Effect of rifampin and itraconazole on the pharmacokinetics of zanubrutinib (a Bruton's tyrosine kinase inhibitor) in Asian and non-Asian healthy subjects

PURPOSE: Zanubrutinib (BGB-3111) is a potent Bruton’s tyrosine kinase inhibitor with promising clinical activity in B-cell malignancies. Zanubrutinib was shown to be mainly metabolized through cytochrome P450 3A (CYP3A) in vitro. We evaluated the effect of steady-state rifampin (a strong CYP3A induc...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Cancer Chemother Pharmacol
Главные авторы: Mu, Song, Tang, Zhiyu, Novotny, William, Tawashi, Manal, Li, Ta-Kai, Ou, Ying, Sahasranaman, Srikumar
Формат: Artigo
Язык:Inglês
Опубликовано: Springer Berlin Heidelberg 2019
Предметы:
Original Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC7015960/
https://ncbi.nlm.nih.gov/pubmed/31875923
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-019-04015-w
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы